Validation of the association of RECIST changes with survival in men with metastatic castration resistant prostate cancer treated on SWOG study S0421

BACKGROUND: Phase II trials evaluating new agents for metastatic castration-resistant prostate cancer (mCRPC) have relied on bone scan and prostate specific antigen (PSA) changes to assess activity. Given the increasing detection of measurable disease, RECIST changes warrant consideration to evaluat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Genitourin Cancer
Main Authors: Sonpavde, Guru, Pond, Gregory R., Plets, Melissa, Tangen, Catherine M., Hussain, Maha H.A., Lara, Primo N., Goldkorn, Amir, Garzotto, Mark G., Mack, Philip C., Higano, Celestia S., Vogelzang, Nicholas J., Thompson, Ian M., Twardowski, Przemyslaw W., Van Veldhuizen, Peter J., Agarwal, Neeraj, Carducci, Michael A., Monk, J. Paul, Quinn, David I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5734863/
https://ncbi.nlm.nih.gov/pubmed/28579151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.05.014
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados